| COMMENTS |
Rhodia ChiRex. Shott Ian D., Mfg div. Pres. One of the biggest problems in pharma. Mfg is avoiding prodt cross-contamination. In the environment of multipurpose plants, that’s achieved by “ages of cleaning, decontaminating, & testing, to the extent that a plant may spend almost half the year being cleaned & changed over” “If key parts of the process – forming the prodt & isolating the prodt – were in VERY SMALL, HIGH-VELOCITY UNITS that could be plugged in & unplugged, then small units could be dedicated or semidedicated to SINGLE PRODTS, & they could be cleaned off-line” |
| CLASSIFICATION | Market |
| DESCRIPTION |
The microreactor is the same size as a videotape. It forms the heart of micro reaction systems commercialized by Co. One system can be used for different processes simply by changing the Cytos unit, which can be plugged in & unplugged. In Co.’s microreactor systems only the reactor is in microscale. The valves, pumps & other peripherals are not integrated. |
| UPDATE | 03.02 |
| USES |
Co described applications of MODULAR MICROREACTOR systems. Co claims that microreaction systems are widely applicable. About 70% of the organic chemistry being done now by conventional methods can be done in these systems. The major limitation is with reactions that involve SOLIDS. CIPROFLOXACIN. “Bayer told Co. that when they had to provide preclinical & Phase I clinical samples, they could have saved a lot of months in process development if they had used these reactors”. Co has applied for a process PATENT, which it could LICENSE to other manufacturers when Bayer’s patent EXPIRES. |
| CONTACT | This data is not available for free |
| LITERATURE REF. | This data is not available for free |
| MARKETING BY | This data is not available for free |
| PRODUCTION BY | This data is not available for free |
| TRADEMARK | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |